Literature DB >> 22185714

Anticoagulation control quality affects the D-dimer levels of atrial fibrillation patients.

Yosuke Nakatani1, Koichi Mizumaki, Kunihiro Nishida, Tadakazu Hirai, Masao Sakabe, Yoshitaka Oda, Shuji Joho, Akira Fujiki, Takashi Nozawa, Hiroshi Inoue.   

Abstract

BACKGROUND: Anticoagulation control quality affects the incidence of thromboembolic events in atrial fibrillation (AF) patients. However, the effects of anticoagulation control quality on the prothrombotic state of AF patients are unclear. METHODS AND
RESULTS: Ninety-five AF patients who had been treated with warfarin were prospectively followed-up for 449 ± 92 days. We analyzed whether time in the therapeutic range (TTR) of the international normalized ratio (INR) of prothrombin time, percentage of INR values in the range (%INR), and coefficient of variation of INR values (CV-INR) were related to D-dimer levels. The mean values of TTR, %INR, and CV-INR were 62%, 59%, and 0.19, respectively, and their median values were 67%, 63%, and 0.19, respectively. TTR was significantly correlated with %INR (R(2) = 0.917, P<0.01), but not with CV-INR (R(2) = 0.050, P = 0.26). The mean and median D-dimer levels were 0.79 and 0.60 µg/ml, respectively. Low TTR, low %INR, and high CV-INR were found to contribute to high D-dimer levels (P = 0.02, 0.03, and 0.02, respectively).
CONCLUSIONS: In AF patients treated with warfarin, not only the duration outside the target INR range, but also the fluctuation in INR level may influence the prothrombotic state.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22185714     DOI: 10.1253/circj.cj-11-0885

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  8 in total

1.  Inflammation and hemostasis in atrial fibrillation and coronary heart disease: The REasons for Geographic And Racial Differences in Stroke study.

Authors:  Wesley T O'Neal; Elsayed Z Soliman; George Howard; Virginia J Howard; Monika M Safford; Mary Cushman; Neil A Zakai
Journal:  Atherosclerosis       Date:  2015-09-08       Impact factor: 5.162

2.  Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population.

Authors:  Fumihiko Kitagawa; Junnichi Ishii; Shinya Hiramitsu; Hiroshi Takahashi; Ryuunosuke Okuyama; Hideki Kawai; Takashi Muramatsu; Masahide Harada; Sadako Motoyama; Hiroyuki Naruse; Shigeru Matsui; Masayoshi Sarai; Mutsuharu Hayashi; Eiichi Watanabe; Hideo Izawa; Yukio Ozaki
Journal:  Heart Vessels       Date:  2016-10-28       Impact factor: 2.037

3.  Relevance of transthoracic left atrial appendage wall velocity measurement in addition to left atrial volume for noninvasive and quantitative assessment of left atrial thrombogenesis in patients with atrial fibrillation and normal D-dimer levels.

Authors:  Naoyasu Yoshida; Mitsunori Okamoto; Hidekazu Hirao; Kazuyoshi Suenari; Kiyomi Nanba; Mio Uchida; Ryo Yamazato; Yuichiro Watari; Yukihiro Fukuda; Hironori Ueda
Journal:  J Med Ultrason (2001)       Date:  2015-12-14       Impact factor: 1.314

Review 4.  Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review.

Authors:  Elizabeth S Mearns; Jessica Hawthorne; Ju-Sung Song; Craig I Coleman
Journal:  BMJ Open       Date:  2014-06-20       Impact factor: 2.692

5.  Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.

Authors:  Géric Maura; Pierre-Olivier Blotière; Kim Bouillon; Cécile Billionnet; Philippe Ricordeau; François Alla; Mahmoud Zureik
Journal:  Circulation       Date:  2015-07-21       Impact factor: 29.690

6.  The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study.

Authors:  Takayuki Jujo-Sanada; Nobuhiro Tanabe; Seiichiro Sakao; Toshihiko Sugiura; Ayumi Sekine; Rintaro Nishimura; Rika Suda; Akira Naito; Hideki Miwa; Keiko Yamamoto; Akane Sasaki; Akane Matsumura; Ryogo Ema; Hajime Kasai; Fumiaki Kato; Koichiro Tatsumi
Journal:  Pulm Circ       Date:  2017-06-12       Impact factor: 3.017

7.  Burden of comorbidities among Japanese patients with atrial fibrillation: a case study of dyspepsia.

Authors:  Yoshikazu Kinoshita; Marco Dibonaventura; Bruno Rossi; Kazuya Iwamoto; Edward C Y Wang; Jean-Baptiste Briere
Journal:  Clin Exp Gastroenterol       Date:  2013-05-20

8.  Baseline D-Dimer Levels as a Risk Assessment Biomarker for Recurrent Stroke in Patients with Combined Atrial Fibrillation and Atherosclerosis.

Authors:  Kang-Ho Choi; Woo-Keun Seo; Man-Seok Park; Joon-Tae Kim; Jong-Won Chung; Oh Young Bang; Geong-Moon Kim; Tae-Jin Song; Bum Joon Kim; Sung Hyuk Heo; Jin-Man Jung; Kyungmi Oh; Chi Kyung Kim; Sungwook Yu; Kwang Yeol Park; Jeong-Min Kim; Jong-Ho Park; Jay Chol Choi; Yang-Ha Hwang; Yong-Jae Kim
Journal:  J Clin Med       Date:  2019-09-13       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.